| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 37 | 2023 |
| DrugMap: A quantitative pan-cancer analysis of cysteine ligandability M Takahashi, HB Chong, S Zhang, TY Yang, MJ Lazarov, S Harry, ... Cell, 2024 | 4 | 2024 |
| Epigenetic Silencing of LRP2 Is Associated with Dedifferentiation and Poor Survival in Multiple Solid Tumor Types MQ Rasmussen, G Tindbæk, MM Nielsen, C Merrild, T Steiniche, ... Cancers 15 (6), 1830, 2023 | 1 | 2023 |
| TBK1 inhibition enhances CAR-T cell efficacy against patient-derived organotypic tumor spheroids L Maggs, Y Sun, G Cattaneo, M Ventin, F Chen, MQ Rasmussen, X Wang, ... Cancer Research 84 (6_Supplement), 4003-4003, 2024 | | 2024 |
| Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy OY Revach, AM Cicerchia, O Shorer, B Petrova, S Anderson, J Park, ... bioRxiv, 2024.02. 12.579184, 2024 | | 2024 |
| 561 Targeting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy OY Revach, A Cicerchia, M Sade-Feldman, S Anderson, B Petrova, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
| Developmental Expression of the Cell Cycle Regulator p16INK4a in Retinal Glial Cells: A Novel Marker for Immature Ocular Astrocytes? C Martinez-Fernandez de la Camara, T Storm, A Salman, T Burgoyne, ... Journal of Histochemistry & Cytochemistry 71 (6), 301-320, 2023 | | 2023 |
| Class I HLA-independent lysis of immunotherapy-resistant melanoma by CD8 T cells H Xie, A Jiang, A Jenney, Y Sun, T Sharova, M Sade-Feldman, O Revach, ... Cancer Research 83 (7_Supplement), 4072-4072, 2023 | | 2023 |
